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Abstract: Background and Objectives: Obstructive sleep apnea syndrome (OSAS) and chronic ob-
structive pulmonary disease (COPD) are usually associated with multi-morbidity. The aim of this
study was to retrospectively investigate the prevalence of comorbidities in a cohort of patients
with OSAS and COPD-OSAS overlap syndrome (OS) patients and to explore differences between
these two groups. Materials and Methods: Included were consecutive OS patients and OSAS patients
who had been referred to our sleep laboratory, and were matched in terms of sex, age, BMI, and
smoking history. Presence of comorbidities was recorded based on their medical history and after
clinical and laboratory examination. Results: The two groups, OS patients (n = 163, AHI > 5/h and
FEV1/FVC < 0.7) and OSAS patients (n = 163, AHI > 5/h, and FEV1/FVC > 0.7), did not differ in
terms of apnea hypopnea index (p = 0.346), and oxygen desaturation index (p = 0.668). Compared to
OSAS patients, OS patients had lower average SpO2 (p = 0.008) and higher sleep time with oxygen
saturation <90% (p = 0.002) during sleep, and lower PaO2 (p < 0.001) and higher PaCO2 (p = 0.04)
in wakefulness. Arterial hypertension was the most prevalent comorbidity for both OS and OSAS,
followed by dyslipidemia, cardiovascular disease (CVD) and diabetes. OS was characterized by a
higher prevalence of total comorbidities (median (IQR):2 (1–3) vs. 2 (1–2), p = 0.033), which was due
to the higher prevalence of CVD (p = 0.016) than OSAS. No differences were observed in other comor-
bidities. Conclusions: In OS patients, nocturnal hypoxia and impaired gas exchange in wakefulness
are more overt, while a higher burden of CVD is observed among them in comparison to sex-, age-
and BMI-matched OSAS patients.
Keywords: obstructive sleep apnea syndrome; chronic obstructive pulmonary disease; overlap
syndrome; comorbidities; cardiovascular disease
1. Introduction
Obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD)
are highly prevalent in the general population, with an occurrence of approximately
10% for each [1]. Nevertheless, both are frequently under-diagnosed, leading to several
medical complications and increased social and financial burden [2,3]. OSA is defined
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as complete (apneas) or partial (hypopneas) airflow cessation during sleep leading to
nocturnal oxygen desaturations, sleep fragmentation, and daytime sleepiness [4], while
COPD is characterized by persistent airflow obstruction in association with a history of
risk factors: mainly smoking as well as environment pollution and occupational exposure
to dusts and fumes [5].
Coexistence of obstructive sleep apnea syndrome (OSAS) and COPD in the same
patient was first introduced by Flenley in 1985 and is termed as overlap syndrome (OS)
since then [6]. The prevalence of OS is estimated at 1–3.6% in the general population, with
a higher occurrence among those patients who exhibit either OSAS or COPD [7]. Patients
with OS demonstrate poorer quality of life than age-matched COPD patients and are more
likely to express worse indices of sleep hypoxia than OSAS patients [7]. Furthermore, OS
patients are exposed to higher risk for death when OSAS is left untreated as compared with
COPD only individuals [8], while increased healthcare utilization is more often observed
in OS than COPD patients [9].
Both diseases share and/or interact with common risk factors such as increasing age,
male gender, smoking, and obesity [10]. Interestingly, accumulating evidence also indicates
that both OSAS and COPD are usually accompanied by several comorbidities; in particular
advanced age and the aforementioned shared risk factors are the main cause for this [11,12].
In addition, recent studies have shown that patients with OS are also frequently affected
from cardiometabolic disorders [13,14]. Specifically, OS is often related with either an
increased risk of cardiovascular disease (CVD) [15], or with established CVD [16], and
mainly pulmonary hypertension (PH) [17], which is the best studied comorbidity in this
specific population. Decreased oxyhemoglobin saturation during sleep and wakefulness,
impaired lung function, increased oxidative stress, as well as tobacco exposure, reduced
physical activity and increased body mass index (BMI) are amongst the recognized factors
which contribute to the development of CVD in patients with OS [10]. In any case, should
patients be afflicted by both OSAS and COPD, the result is expected to be more detrimental
in terms of coexisting diseases than patients who suffer from either OSAS or COPD alone.
However, until now there has been a lack of evidence about the exact prevalence of
comorbidities, apart from CVD, in patients with OS. The aim of this case–control study
was to assess the prevalence of comorbidities in a group of consecutive patients diagnosed
with OS, at the time of their first evaluation at a tertiary university hospital, compared to
patients with OSAS, and to explore potential differences between these two groups.
2. Materials and Methods
2.1. Patients
A total of 163 consecutive patients who were diagnosed with OS from 2011 to 2018,
at the sleep laboratory of the University General Hospital of Alexandroupolis, Greece,
were retrospectively enrolled in the study. The following inclusion criteria were applied:
consecutive patients with COPD and OSAS, i.e., OS, newly diagnosed via pulmonary
function testing and polysomnography, aged 40 years or older; current or ex-smokers with
at least ten pack-years smoking history; and available and complete medical records for
assessment of comorbidities. The exclusion criteria were central sleep apnea syndromes
and inability to extract information on patients’ comorbid illnesses.
After applying the abovementioned criteria which resulted in the enrollment of
163 consecutive OS patients, a one-to-one sex-, age- and BMI- matching procedure re-
sulted in another 163 patients, diagnosed with OSAS without COPD in the same period.
The study protocol was approved by the institutional ethics committee and all procedures
were conducted in accordance with the Helsinki Declaration of Human Rights [18]. Written
informed consent was obtained from all participants.
All patients were assessed for chronic respiratory symptoms, sleep habits, presence of
other comorbidities, current and previous medication use, and tobacco exposure, as well
as alcohol consumption. A focused clinical examination, that included measurement of
anthropometric characteristics, vital signs, and respiratory assessment, was performed.
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Briefly, parameters such as height, weight, neck circumference, hip and waist circumference,
waist/hip circumference ratio, and body mass index (BMI) were measured as part of routine
examination at every patient’s visit.
In addition, lung function was evaluated by pulmonary function testing, via a spirom-
etry device (Chest Co., Tokyo, Japan), and analysis of arterial blood gases, which were
collected from the patients’ radial artery, using an ABL3000 auto-analyzer (Radiometer Co.,
Tokyo, Japan). Cardiac evaluation included a routine 12-lead electrocardiogram the night
before polysomnography in all subjects.
The diagnosis of COPD was established in the setting of a post-bronchodilator
FEV1/FVC ratio of less than 0.7, combined with chronic symptoms, such as dyspnea,
cough and/or sputum production, and in association with a history of exposure to risk
factors [19].
Subjective daytime sleepiness was evaluated via the use of the validated Greek version
of the Epworth Sleepiness Scale (ESS) [20], which is a self-administered questionnaire
assessing the probability of falling asleep in a variety of daily circumstances (maximum
score: 24; score > 10: excessive daytime sleepiness).
2.2. Polysomnography
All included participants underwent an attended 8 h overnight polysomnography
(PSG) (from 22:00 to 06:00), which was performed using a laboratory-based instrument
(Alice® 4, Philips Respironics, Murrysville, PA, USA). PSG included a standard montage
of electroencephalogram, electro-oculogram, electromyogram (submental and bilateral
tibial), and electrocardiogram signals. Monitoring of respiratory events was performed
using combined oronasal thermistors and thoracic/abdominal strain gauges, while oxy-
hemoglobin saturation was assessed using a pulse oximeter placed on the index finger.
Apneas, hypopneas, and electroencephalogram recordings were manually scored accord-
ing to standard criteria [21]. Apnea was defined as a ≥90% of reduction in airflow for
at least 10 s. Hypopnea was defined as a ≥30% reduction in airflow for at least 10 s in
combination with oxyhemoglobin desaturation of at least 3% or an arousal registered by
the electroencephalogram. The apnea–hypopnea index (AHI) was regarded as the average
number of apneas and hypopneas per hour of PSG-recorded sleep time. OSAS was defined
as AHI ≥ 5/h accompanied by related symptoms [21].
2.3. Statistical Analysis
All statistical analyses were performed using Statistical Package for Social Sciences
17.0 (SPSS Inc. Released 2008. SPSS Statistics for Windows, version 17.0, Chicago, IL, USA).
Normality of distribution for continuous variables was tested by the Kolmogorov–Smirnov
test. Normally distributed quantitative data were expressed as mean ± standard deviation
(SD) and those with skewed distribution as median (Interquartile range, IQR: 25th–75th
percentile). Comparison of percentages between groups was performed using the chi-
square test. Comparisons between means were determined with Student’s t-test. In case
of skewed distribution, the non-parametric Mann–Whitney test was applied. Statistical
significance was defined at 5% (two-tailed p < 0.05).
3. Results
In total, 163 consecutive OS patients (AHI > 5/h and FEV1/FVC < 0.7) were en-
rolled from 2011 to 2018 and compared to 163 patients with OSAS (AHI > 5/h and
FEV1/FVC > 0.7), after a one-to-one sex, age-, and BMI-matching process during the same
study period (Figure 1). The two groups did not differ in terms of: sex (males/females:
139/24 for OSAS; 138/25 for OS, p = 0.877), age (59 (51.5–66.5) years for OSAS, 61 (54–68)
years for OS, p = 0.221), BMI (36.1 (32–39.2) Kg/m2 for OSAS, 36.2 (32.1–41) Kg/m2 for
OS, p = 0.496), and smoking history (p = 0.412 for current smokers, and p = 0.734 for ex-
smokers). No differences were observed between the two groups in the anthropometrics’
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characteristics except for higher waist circumference in OS patients (122 (110.5–129) for
OSAS vs. 126 (114–135) for OS, p = 0.018).
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Figure 1. The study flowchart. BMI: body mass index; COPD: chronic obstructive pulmonary disease;
OS: overlap syndrome; OSAS: obstructive sleep apnea syndrome; PFTs: pulmonary function testing;
PSG: polysomnography.
Compared to OSAS patients, OS patients demonstrated lower average sleep oxyhe-
moglobin (p = 0.008), higher sleep time with oxygen saturation <90% (p = 0.02) during
sleep and lower levels of PaO2 (p < 0.001), and PaCO2 (p < 0.04) during wakefulness. As
expected, impaired lung function was noticed in pulmonary function tests during wake-
fulness, expressed by Forced Expiratory Volume at 1 s (FEV1) and Forced Vital Capacity
(FVC) in OS compared with OSAS (p < 0.001 for both). Table 1 displays the anthropometric
characteristics, whereas Tables 2 and 3 report the PSG findings and the results of pulmonary
function tests, respectively.
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Table 1. Comparison of anthropometric characteristics between patients with obstructive sleep apnea







Gender (males/females) 139/24 138/25 0.877
Age (years) 59 (51.5–66.5) 61 (54–68) 0.221
BMI (kg/m2) 36.1 (32–39.2) 36.2 (32.1–41) 0.496
Neck circumference (cm) 45 (42–48) 45 (42–48) 0.922
Waist circumference (cm) 122 (110.5–129) 126 (114–135) 0.018
Hip circumference (cm) 119 (111–126) 118 (111–128 0.972
WHR 0.86 (0.80–0.96) 0.89 (0.80–0.96) 0.377
Smoking status
Never smokers (%) 31.3% 25.2% 0.219
Current smokers (%) 63.1% 61.3% 0.631
Ex-smokers (%) 36.9% 38.7% 0.734
Abbreviations: BMI: Body mass index; WHR: Waist to hip ratio.
Table 2. Comparison of sleep characteristics between patients with obstructive sleep apnea syndrome







Recording time (min) 378 (356–404) 383 (336–402) 0.665
TST (min) 306 (248.5–335.5) 309.8 (253.3–349.6) 0.152
N1 (%) 18.8 (9–34.5) 15.6 (7.8–31.9) 0.308
N2 (%) 59.8 (45.6–72.4) 60.6 (45.4–73.3) 0.646
N3 (%) 5.6 (0–14.6) 6.3 (0.03–12.9) 0.939
REM (%) 9.6 (3.9–14.5) 7.6 (2.4–15) 0.275
AHI (events/h) 35.2 (16.8–62.3) 36.8 (16–61) 0.346
ODI (events/h) 46.3 (26.5–63.1) 45.9 (22.5–69.9) 0.668
Aver SpO2 (%) 92 (90–93) 91 (88–93) 0.008
Min SpO2 (%) 78 (70–83) 75 (66.3–82) 0.100
T < 90% (min) 12.1 (3.4–35.9) 22.3 (4.8–55.1) 0.020
Arousal index 31.3 (22–45.7) 27.3 (12–45.2) 0.110
Sleep efficiency (%) 80.8 (69.2–86.6) 81.8 (69.2–89.4) 0.300
ESS score 9 (6–14) 9 (6–14) 0.988
Abbreviations: AHI: apnea hypopnea index; Aver SpO2: average oxyhemoglobin saturation; ESS: Epworth
sleepiness scale; Min SpO2: minimum oxyhemoglobin saturation; N1: sleep stage 1; N2: sleep stage 2; N3: sleep
stage 3; ODI: oxygen desaturation index, REM: rapid eye movement; TST: total sleep time; T < 90%: time with
oxyhemoglobin saturation <90%.
In both OS and OSAS, hypertension was the most prevalent comorbidity (n = 96
(58.9%) for OSAS vs. n = 101 (62%) for OS, p = 0.571), followed by dyslipidemia (n = 46
(28.2%) for OSAS vs. n = 52 (31.9%) for OS, p = 0.469), and diabetes (n = 29 (17.8%) for
OSAS vs. n = 37 (22.7) for OS, p = 0.270). OS was characterized by a higher prevalence
of total comorbidities (median: 2 (IQR: 1–3) vs. 2 (IQR: 1–2), p = 0.033) and particularly
CVD, which was the composite of coronary artery disease, heart failure, cerebrovascular,
and peripheral artery disease than OSAS (n = 22 (13.5%) for OSAS vs. 39 (23.9%) for OS,
p = 0.016). No differences were observed in the prevalence of other comorbidities between
the two groups. Table 4 presents all comorbidities that were found in our study analysis in
OSAS and OS patients.
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Table 3. Respiratory function during wakefulness between patients with obstructive sleep apnea







FEV1 (% predicted) 97.8 (86.8–110) 68.1 (51.4–79.3) <0.001
FVC (% predicted) 87.9 (77–100) 73.3 (57.9–89) <0.001
FEV1/FVC (%) 85.8 (82.2–90.4) 67.2 (62.3–69.2) <0.001
Airflow limitation
Mild (%) - 24.5% -
Moderate (%) - 57.7% -
Severe (%) - 17.8% -
pH 7.42 (7.40–7.44) 7.42 (7.41–7.44) 0.827
pO2 (mmHg) 77 (70–83.2) 71.6 (64–79.5) <0.001
pCO2 (mmHg) 41 (39–44) 43 (39–44) 0.040
Abbreviations: FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; pCO2: partial
carbon dioxide pressure; pO2: partial oxygen pressure.
Table 4. Prevalence of comorbidities between patients with obstructive sleep apnea syndrome (OSAS)







Comorbidities total 2 (1–2) 2 (1–3) 0.033
No comorbidities (n, %) 34 (20.9) 24 (14.7) 0.148
Hypertension (n, %) 96 (58.9) 101 (62) 0.571
Cardiovascular disease (n, %) 22 (13.5) 39 (23.9) 0.016
Dementia (n, %) 1 (0.6) 1 (0.6) 1
Cerebrovascular disease (n, %) 2 (1.2) 2 (1.2) 1
Diabetes (n, %) 29 (17.8) 37 (22.7) 0.270
Dyslipidemia (n, %) 46 (28.2) 52 (31.9) 0.469
Atrial fibrillation (n, %) 7 (4.3) 14 (8.6) 0.114
Cancer (n, %) 0 (0) 3 (1.8) 0.082
Depression (n, %) 10 (6.1) 7 (4.3) 0.455
Gastroesophageal reflux (n, %) 7 (4.3) 6 (3.7) 0.777
Connective tissue disease (n, %) 3 (1.8) 6 (3.7) 0.311
Chronic kidney disease (n, %) 1 (0.6) 1 (0.6) 1
Liver disease (n, %) 1 (0.6) 0 (0) 0.317
Osteoporosis (n, %) 3 (1.8) 2 (1.2) 0.652
Hyperuricemia (n, %) 6 (3.7) 4 (2.5) 0.521
Thyroid gland disease (n, %) 13 (8) 18 (11) 0.345
Parkinson disease (n, %) 3 (1.8) 0 (0) 0.082
4. Discussion
The present study highlights important findings in the field of overlap syndrome.
Firstly, patients with OS demonstrate an increased number of concomitant diseases at
their first initial evaluation for sleep-disordered breathing in a sleep laboratory, and higher
prevalence of established CVD in OS compared with sex-, age-, and BMI-matched OSAS
patients. In addition, components of metabolic syndrome such as hypertension, dyslipi-
demia, and diabetes similarly occur in both OS and OSAS. Finally, OS compared with OSAS
patients demonstrate worse indices of sleep hypoxia and gas exchange in wakefulness. To
the best of our knowledge this is the largest study to date on the prevalence of coexisting
diseases in the field of overlap syndrome.
Recent studies have found high occurrence of comorbid diseases in patients with
OS, two of them comparing OS and OSA patients [13,14], two others included OS and
COPD only individuals [8,22], while one examined and compared all three groups [23].
In the most recent study, OS patients found to have higher prevalence of heart failure
Medicina 2021, 57, 1201 7 of 10
than COPD and OSAS subjects (p < 0.01; for all), while coronary artery disease was more
prevalent in OS than OSAS only individuals (p < 0.01) [23]. The findings of this study
are in line with our study, which demonstrate the burden of CVD [23]. Nevertheless, the
authors matched their patients for age and sex, while in our study BMI was also accounted
for in the matching process. In a cross-sectional study [14], that included 38 OS patients
and 38 OSAS patients matched for gender, age, and BMI, OS were frequently affected
by cardiometabolic diseases, namely CVD, hypertension, diabetes mellitus, and dyslipi-
demia, while an increased number of several other comorbidities (≥4) was more often
observed in OS than OSAS patients (11, vs. 4, respectively). Similarly, Lacedonia et al. [13],
in a retrospective study including 989 individuals, of whom 721 had OSAS, 123 OS, and
145 obesity–hypoventilation syndrome, showed that OS are exposed to a higher number of
concomitant diseases in contrast to OSAS. Notably, hypertension was the most prevalent
disease in OS compared with the other two groups, whereas diagnosis of OS was associ-
ated more often with the presence of ≥3 comorbidities compared with OSAS (p < 0.001).
Steveling et al. [22], in a cross-sectional study that included 177 COPD patients, of whom
33 had coexistent OSA, demonstrated among other observations that diabetes mellitus and
arterial hypertension were more frequently present in patients with overlap syndrome than
in COPD only patients. Finally, in the landmark study of Marin et al. in the field of overlap
syndrome, a higher proportion of patients with OS received antihypertensive treatment and
statin therapy and had higher scores in Charlson comorbidity index compared with COPD
individuals, indicating frequent presence of multi-morbidity in OS [8]. These findings
are in line with our results, underlining that OS is related with a significant burden of
cardiometabolic disorders than OSAS or COPD alone.
In fact, this could be partially explained by the concurrent attribution of COPD and
OSAS in the same patient toward the pathogenesis of multiple diseases, particularly
CVD [24]. Both diseases are known to predispose to an increased load of systemic in-
flammation, oxidative stress, endothelial dysfunction and sympathetic over-activity; all
are implicated in the pathophysiology of numerous diseases [25,26]. Alone or combined,
these mechanisms may increase the risk of systemic hypertension, glucose intolerance,
CVD, arrhythmias, neurological and endocrine disease, and cancer in COPD and OSAS
patients [11,12]. In a retrospective study [27], that included 146,141 patients with COPD
(mean age 67.2 years) compared to one-to-one matched for age and gender randomly
selected non-COPD controls, showed that COPD presented more comorbidities than con-
trols, and particularly they were highly affected by hypertension (over 70%), followed by
anxiety and depression, diabetes, heart failure, gastroesophageal reflux disease, chronic
kidney disease, and osteoporosis. Notably, a significant number of the investigated COPD
patients had Charlson Index ≥5 compared to non-COPD individuals (15.57% vs. 5.58,
respectively), indicating the increasing burden of accompanied disorders in this population.
Multi-morbidity has also been shown to be highly present in patients with OSAS. Several
studies strongly relate presence of OSAS, and even increasing severity of the syndrome,
with a high occurrence of several comorbidities [11]. In a cross-sectional study [28] in
1929 patients referred to a sleep laboratory for suspected OSAS, of whom 62.1% were
diagnosed with OSAS (AHI > 5/h), increasing OSAS severity was significantly associated
with higher prevalence of heart attack, coronary artery disease, hypertension, diabetes,
and obesity. A large cohort study in the USA [29], enrolling 1,704,905 individuals with a
diagnosis of OSAS from a nationwide database and a matched randomly selected sample of
controls (n = 1,704,417), revealed that OSAS patients had a significantly higher prevalence
of important comorbidities-namely type 2 diabetes, cardiovascular disease, hypertension,
arrhythmias, and depression, than controls and this finding was more apparent with
increasing age.
In the case of OS these patho-physiological phenomena might all simultaneously
emerge resulting in the presence and/or development of co-existing diseases [10], as it is
shown in our study. Regarding pathogenesis of CVD, both COPD and OSAS are linked
with systemic inflammation, oxidative stress, and hyper-coagulopathy, which predispose
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to endothelial dysfunction and atherosclerosis [1,30]. Moreover, COPD via smoking and
OSAS via obesity could further promote development of CVD [1]. All these taken together
multiply the risk of CVD in patients with OS. Indeed, in our study established CVD was
shown to be more often present in OS than OSAS patients (p = 0.016). Despite that there
were no differences in terms of prevalence of other diseases between the OS and OSAS
groups, common comorbidities, such as hypertension, diabetes, and dyslipidemia, were
highly prevalent in the group of patients with OS, corroborating the findings of previous
reports. Specifically, both the studies of Lacedonia et al. [13] and Papachatzakis et al. [14],
assessing the prevalence of comorbidities in OS, reported that besides occurrence of es-
tablished CVD, hypertension, diabetes, and dyslipidemia, all components of metabolic
syndrome, were the most representative comorbidities in this group of patients, indicating
a clear association between OS and cardiometabolic diseases. Interestingly, several other
comorbidities, even in a small portion of OS patients, were found also to be present in
our study analysis, such as thyroid diseases, depression, gastroesophageal reflux, and
connective tissue disease. Perhaps, a future study enrolling more patients with OS could
identify stronger or weaker associations between OS and other comorbidities.
Regarding the breathing function in both wakefulness and during sleep, our findings
have shown that both were worse in the group of patients with OS. Specifically, daytime
O2 and CO2 levels were impaired in OS patients, while parameters of oxygen saturation
during sleep were also poorer in the same group compared with the OSAS patients. In
one of the earlier studies, which was conducted by Chaouat et al. [17], levels of PaO2 were
lower and PaCO2 were higher in awake in OS patients compared with OSAS patients, while
mean SpO2 levels during sleep were significantly decreased in OS than OSAS individuals.
Additionally, other studies have also observed impaired levels of T90% during sleep
in OS compared with OSAS [31,32], similar to our results. Moreover, as expected, and
by definition, pulmonary function testing was markedly decreased in OS patients due
to the presence of COPD. These findings could partially be responsible for the more
frequent occurrence of CVD, but also for the coexistence of arterial hypertension and atrial
fibrillation in the OS group. An increasing body of evidence acknowledges hypoxia and
impaired lung function as important risk factors for the development of CVD, linking also
patho-physiologically various pulmonary disorders with poor CV outcomes [26,33].
Certainly, the present study is subject to several limitations. Firstly, this is cross-
sectional study and hence no specific causality could be extracted regarding the role of
OS on the prevalence of comorbidities. Nevertheless, an association between OS and
multi-morbidity that is more frequently observed in OS compared with OSAS individuals
could be drawn from this study. Secondly, the true prevalence of pulmonary hypertension
(PH), assessed by objective evaluation, could not be demonstrated in the present cohort of
included patients. We only included information regarding the presence or not of cardiovas-
cular disease, including heart failure as one of the components of CVD, based on the history
and/or medical treatment of our patients. Nevertheless, it is now widely known that OS
predisposes more often to PH development compared with OSAS [10]. Another limitation
is the relatively small number of patients with OS and OSAS assessed for the presence of
multiple comorbidities; some of which were even rare to be traced. However, our study
attempted to fill the research gap regarding the burden and the different prevalence rates of
comorbidities between OS and OSAS patient populations. Therefore, large-scale studies are
needed to systematically elucidate the actual burden of multimorbidity in OS and OSAS.
Moreover, information regarding prevalence of comorbidities in COPD only patients were
lacking from our study. A recent study examined the prevalence of cardiovascular disease
in patients with OS compared with COPD (and OSAS), but information was lacking re-
garding the presence of other comorbidities in these patient groups [23]. Therefore, future
evidence is required in order to assess general and specific characteristics, such as PSG
events, outcomes, associated diseases, and mortality, between OS and COPD patients [34].
Of interest, a recent report conducted by an ATS panel of experts in this field suggested
that studies should evaluate differences between either COPD and OS or OSAS and OS
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patients, in order to better elucidate the burden of overlap syndrome in various clinical
aspects [35]. Finally, we could not demonstrate whether treatment with positive airway
pressure (PAP) might have influenced the prevalence of comorbidities in our cohort and
whether PAP therapy could eliminate several coexisting diseases, which are shown to be
associated with either OSA or COPD, and contribute in reducing the cardiometabolic risk.
The latter remains to be investigated in a future prospective study.
5. Conclusions
To conclude, this study shows that OS is accompanied by an increased number of
total comorbidities and a higher prevalence of CVD in comparison to sex-, age-, and
BMI-matched OSAS patients. Thus, investigation of patients with overlap syndrome for
concomitant diseases seems to be highly reasonable at their initial assessment in order for
these disorders to be early identified and properly managed. Ultimately, this approach
might lead to reduced morbidity and mortality of this complex association between OSAS
and COPD.
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